Avantor, Inc. (NYSE:AVTR) provides biopharma, healthcare, and education products. The stock is down significantly so far in 2025 mostly due to analyst downgrades recently after it reported weak Q4 ...

The stock is down significantly so far in 2025 mostly due to analyst downgrades recently after it reported weak Q4 2024 results. Avantor reported Q4 revenues of $1.69 billion, down 2% year-over ...